Although these data do not allow drawing conclusions on TA efficacy, they provide arguments for the safe use of TA for procedures at mucosal sites in patients with inherited RBDs and coagulation factor levels below the threshold for bleeding risk, especially FXI deficiency. The gene discussed is F11; the disease is hyperinsulinemic hypoglycemia, familial, 4.